In Advanced Hepatocellular Carcinoma, Nivolumab Superior for Quality of Life

​In advanced hepatocellular carcinoma (HCC), nivolumab (Opdivo®, Bristol-Meyers Squibb) is superior to sorafenib (Nexavar®, Bayer) with regard to health-related quality of life (HRQOL), according to results of the phase 3 CheckMate 459 trial to be reported on Friday at the 2020 Gastrointestinal Cancers Symposium.For CheckMate 459, 743 patients with advanced HCC were randomized in a 1:1 ratio to receive nivolumab or sorafenib. The researchers reported in September at the 44th European Society for...
Continue reading

Nivolumab for Esophageal Cancer: An Interview With Ken Kato, MD, PhD

Results from a phase 3 trial show that nivolumab significantly improves overall survival compared with chemotherapy in patients who have been previously treated for advanced esophageal squamous cell carcinoma (ESCC). In this interview with i3 Health, Ken Kato, MD, PhD, explains the results from this study, as well as rationale for using nivolumab in ESCC, safety considerations, and the study's implications for oncology practice.What is the most challenging aspect of treating patients with advanc...
Continue reading

Nivolumab Proves Effective in Advanced Esophageal Cancer

According to the results of the phase 3 trial, ATTRACTION-3, nivolumab significantly improves overall survival compared with chemotherapy in patients who have been previously treated for advanced esophageal squamous cell carcinoma. For this study, results of which are published in The Lancet Oncology, researchers enrolled 419 patients from 90 hospital and cancer centers in Denmark, Germany, Italy, Japan, South Korea, Taiwan, the UK, and the USA. Patients with unresectable advanced or recurrent e...
Continue reading

Nivolumab: Five-Year Survival for Melanoma, RCC, and NSCLC

​Five-year overall survival results have now been revealed for nivolumab in advanced melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC)."We report, to our knowledge, the longest combined clinical follow-up for patients with multiple cancer types receiving any anti–PD-L1 drug," the researchers comment in their secondary analysis of data from the phase I CA209-003 trial and expansion cohorts. This trial was the first multidose trial of nivolumab, an immunotherapy drug tha...
Continue reading

Nivolumab for Untreated Advanced Classic Hodgkin Lymphoma

Nivolumab (Opdivo®, Bristol-Myers Squibb), an anti–programmed cell death protein 1 (anti–PD-1) monoclonal antibody, has been previously approved by the FDA for the treatment of refractory classic Hodgkin lymphoma (cHL). Now, in the CheckMate 205 phase 2 clinical trial, nivolumab shows promise in newly diagnosed advanced-stage cHL.In addition to refractory cHL, nivolumab is approved for the treatment of advanced lung cancer, melanoma, advanced kidney cancer, head and neck squamous cell cancer, ad...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.